VTX-067 / Voltron Therap - LARVOL DELTA

A Self-Assembling Vaccine, VTX-067, targeting E6/E7 proteins of Human Papilloma Virus Induces T Cell-Mediated Immune Responses and Inhibits HPV E6/E7 Expressing Tumor Growth in a C57/B6 Mouse Model. (IMMUNOLOGY 2024) - "Our study demonstrated that VTX-067 is safe and well-tolerated in mice, and three dose levels of VTX-067 provided both statistically significant T cell-mediated viral antigen-specific responses and increases in overall survival and tumor volume reduction."

Preclinical • Dermatology • Head and Neck Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Tuberculosis • CD4 • CD8 • HSPA9 • IFNG

A novel self-assembling vaccine, VTX-067, targeting E6/E7 proteins of human papilloma virus induces T cell immune responses and inhibits HPV E6/E7 expressing tumor growth in a C57/B6 mouse model (SITC 2023) - "Conclusions Overall, our study demonstrated that three dose levels of VTX-067 all provided significant antigen specific T cell responses, increases in overall survival and reduction of tumor volume. We believe these data, in addition to previously published work by our team on a Lassa Fever Virus vaccine,1 support the view that our self-assembling vaccine platform is potentially relevant to both infectious disease and cancer targets."

Preclinical • Head and Neck Cancer • Oncology • Solid Tumor • CD4 • CD8 • HSPA9 • IFNG

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study (PRNewswire) - "Voltron Therapeutics, Inc., a Lucius Partners portfolio company...announced that data from the previously announce Study '098 demonstrated clear Proof-of Concept for VTX-067 in the treatment of HPV related cancers. This is a well-validated murine model of HPV related cancers...Results of the study demonstrated: Improved Overall Survival: VTX-067/SAV had a highly significant, positive survival effect in the TC-1 tumor injected mice. Tumor volume reduction: VTX-067 significantly reduced TC-1 tumor volume. Dose response: there was a clear dose-response to SAV, with the overall best survival benefit to the TC-1 tumor bearing mice at the highest dose of SAV. Safety Profile: the SAV construct once again demonstrated it is well tolerated with no observed reactogenicity."

Preclinical • Oncology

Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-Oncology (PRNewswire) - "Results have demonstrated that the SAV construct significantly increased both helper and cytotoxic T cell responses to the vaccine targeted antigens, when compared to controls. These proof-of-concept efforts utilizing the SAV platform will drive continued development of both oncology and infectious disease targeted vaccines....We aim to file an IND for at least one cancer indication in the coming months."

IND • Preclinical

Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO) (GlobeNewswire) - "Laidlaw Venture Partners...today announced a strategic development agreement with Translational Drug Development (TD2), a precision oncology contract research organization (CRO)...'Our initial project will focus on VaxCelerate in the ovarian cancer setting with additional consideration being given to potential future opportunities in NSCLC, pancreatic cancer, head and neck cancer and mesothelioma,' said Pat Gallagher, Managing Partner at LVP and CEO of Voltron."

Licensing / partnership • Gastrointestinal Cancer • Gynecologic Cancers • Head and Neck Cancer • Lung Cancer • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer